Jump to main content
Jump to site search

Issue 88, 2016, Issue in Progress
Previous Article Next Article

Lipid nanocarrier-based transport of docetaxel across the blood brain barrier

Author affiliations

Abstract

Successful treatment of brain cancer remains a formidable challenge in neuroscience research due to sub-therapeutic permeation of conventional chemotherapeutics across the blood–brain barrier (BBB). By optimizing various conditions and process parameters, we developed a phospholipid based nanosize carrier (NL) encapsulating docetaxel (DTX) and investigated its BBB crossing potential, both qualitatively and quantitatively, in vivo. The optimized NLs had a nanosize below 100 nm, smooth surface with intact lamellarity, 7.8% drug loading and a sustained drug release profile in vitro. Pharmacokinetic and biodistribution data showed an enhanced residence time of the drug in blood and efficient permeation of the drug from the DTX loaded NL through the BBB, as compared to free DTX. The technetium-99m labeled NL effectively crossed the BBB and accumulated in the brain tissue in a time dependant manner compared to technetium-99m labeled DTX. NL may provide a promising platform for an improved management of brain cancer.

Graphical abstract: Lipid nanocarrier-based transport of docetaxel across the blood brain barrier

Back to tab navigation

Article information


Submitted
25 Jun 2016
Accepted
30 Aug 2016
First published
30 Aug 2016

RSC Adv., 2016,6, 85261-85274
Article type
Paper

Lipid nanocarrier-based transport of docetaxel across the blood brain barrier

B. S. Satapathy, B. Mukherjee, R. Baishya, M. C. Debnath, N. S. Dey and R. Maji, RSC Adv., 2016, 6, 85261
DOI: 10.1039/C6RA16426A

Social activity

Search articles by author

Spotlight

Advertisements